MedTrace Logo

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

NCT03013218 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2025-08-01

No results posted yet for this study

Summary

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

Conditions

Interventions

DRUG

Evorpacept (ALX148)

Evorpacept (ALX148)

DRUG

Pembrolizumab

Keytruda

DRUG

Trastuzumab

Herceptin

DRUG

Rituximab

Rituxan

DRUG

Ramucirumab + Paclitaxel

Standard of care chemotherapy

DRUG

5-FU + Cisplatin

Standard of care chemotherapy

Sponsors & Collaborators

  • ALX Oncology Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-03
Primary Completion
2022-02-01
Completion
2025-07-08
FDA Drug
Yes

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03013218 on ClinicalTrials.gov